Lately, one of America's leading pharmaceutical companies can't catch a break from Wall Street. Shares of Vertex ...
A non-opioid pain medication made by Vertex Pharmaceuticals has received approval ... It will use Journavx as its brand name. GET FOX BUSINESS ON THE GO BY CLICKING HERE Vertex CEO Reshma ...
A novel Vertex Pharmaceuticals drug that takes a new ... will be marketed under the brand name Journavx. “Today’s approval is an important public health milestone in acute pain management ...
The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals' Journavx for short-term pain that often follows surgery or injuries. It’s the first new pharmaceutical approach to ...
In a report released today, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research ...
Vertex Pharmaceuticals (VRTX – Research Report) received a Buy rating and a $480.00 price target from Cantor Fitzgerald analyst Olivia Brayer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results